PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer - Majewski, IJ; Nuciforo, P; Mittempergher, L (J Clin Oncol, 2015)
et al.